Maravai Lifesciences price target lowered to $10 from $12 at Craig-Hallum

Craig-Hallum analyst Matt Hewitt lowered the firm’s price target on Maravai Lifesciences (MRVI) to $10 from $12 and keeps a Buy rating on the shares following quarterly results. The firm noted that investors should take a closer look at the company, as they are well-positioned to benefit from the industry’s shift toward repatriation of pharma manufacturing and the FDA’s new AI/modeling initiative-driving demand for the company’s specialized products and services.